Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Pre-Tax Margin
Income before tax as a percentage of revenue.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026
Pre-tax margin widens to 6.5%
Pre-tax margin was 6.5% in Q1 FY2026, up 15.2 pp from a year earlier. On a trailing-twelve-month basis it was -1.7%, up 7.6 pp year over year. Over 3 fiscal years it widened by 36.7 pp.
Context
- Pre-tax margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -5.7%
- Year-over-year change
- +4.1pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -5.7% | +4.1pp |
| FY2024 | 2024-12-31 | -9.8% | -7.6pp |
| FY2023 | 2023-12-31 | -2.2% | +40.3pp |
| FY2022 | 2022-12-31 | -42.4% | -33.5pp |
| FY2021 | 2021-12-31 | -9.0% | — |
Pre-Tax Margin vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 pre-tax margin of -1.7% is the 3rd highest of the 8 companies compared; the peer median is -24.5%.
- Its year-over-year change of +7.6 pp is the 4th highest of 8, against a peer median of +6.5 pp.
- Over three fiscal years its change of +36.7 pp compares with a peer median of +292.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 109.1% | +294.8 pp | +345.2 pp | |
| LTM Mar 2026 | 5.4% | +6.5 pp | -3.9 pp | |
| LTM Mar 2026 | -1.7% | +7.6 pp | +36.7 pp | |
| LTM Mar 2026 | -16.2% | +29.3 pp | +1523.3 pp | |
| LTM Sep 2026 | -24.5% | -4.2 pp | +292.5 pp | |
| LTM Mar 2026 | -37.5% | +530.6 pp | +73239.9 pp | |
| LTM Sep 2026 | -56.7% | -29.9 pp | +3.7 pp | |
| LTM Mar 2026 | -90.5% | +2.2 pp | +108.3 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ETON) | -24.5% | +6.5 pp | +292.5 pp | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.83M | 21.25M | 31.64M | 39.01M | 79.95M |
| Cost of Revenue | 2.62M | 6.93M | 10.58M | 15.6M | 37.21M |
| Gross Profit | 19.21M | 14.32M | 21.06M | 23.41M | 42.74M |
| Gross Margin | 88.0% | 67.4% | 66.6% | 60.0% | 53.5% |
| Research & Development | 6.24M | 4M | 3.32M | 3.26M | 7.77M |
| Selling, General & Admin | 14.47M | 18.58M | 18.93M | 22.75M | 35.82M |
| Operating Expenses | 20.7M | 22.58M | 22.25M | 26.01M | 42.67M |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| EBITDA | (1.49M) | (7.25M) | 212K | (657K) | 4.27M |
| EBITDA Margin | -6.8% | -34.1% | 0.7% | -1.7% | 5.3% |
| Operating Income | (1.5M) | (8.26M) | (1.19M) | (2.6M) | 72K |
| Operating Margin | -6.8% | -38.9% | -3.8% | -6.7% | 0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.04M | 955K | 1.06M | 2.01M | 4.78M |
| Other Income / Expenses | (460K) | (761K) | 503K | (1.21M) | (4.63M) |
| Income Before Tax | (1.96M) | (9.02M) | (689K) | (3.81M) | (4.56M) |
| Pre-Tax Margin | -9.0% | -42.4% | -2.2% | -9.8% | -5.7% |
| Income Tax Expense | 0 | 0 | 247K | 15K | 43K |
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Net Margin | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
| EPS (Basic) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| EPS (Diluted) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| Weighted Avg Shares | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
| Weighted Avg Shares (Diluted) | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.